Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database

Auteur(s) : Mian H, LeBlanc R, Louzada M, Masih-Khan E, McCurdy A, Venner CP, Stakiw J, Kardjadj M,Jimenez-Zepeda VH, Sebag M, White D, Aslam M, Song, Reiman A, Kotb R, Gul E, Reece D

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Auteur(s) : McCurdy A, Louzada M, Venner CP, Visram A, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, LeBlancR, Sebag M, Song K, White D, MianH, Stakiw J, Reiman A, Aslam M, KotbR, Gul E, Reece D.

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

Auteur(s) : Capra M, Martin T, Moreau P, Baker R, Pour L, Min CK, Leleu X, Mohty M, Segura MR, Turgut M, LeBlanc R, et al.

Outcomes of daratumumab in the treatment of multiple myeloma: a retrospective cohort study from the Canadian Myeloma Research Group-database

Auteur(s) : LeBlanc R, Mian H, ReeceD, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, McCurdy A, Song K, Sebag M, Louzada M, WhiteD, Stakiw J, Kotb R, Reiman A, AslamM, Gul E and Venner CP.

Survival and outcomes of newly-diagnosed multiple myeloma patients stratified by transplant status 2007-2018: Retrospective analysis from the Canadian Myeloma Research Group Database

Auteur(s) : Mian M, Reece D, Masih-Khan E, McCurdy A, Kardjadj M, Jimenez-Zepeda VH, Song K, Louzada M, LeBlanc R, Sebag M, White D, Stakiw J, Reiman A, Kotb R, Aslam M, Gul E and Venner CP.

Sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: A report from the Canadian Myeloma Research Group (CMRG) Database

Auteur(s) : McCurdy A, Venner C, Masih-Khan E, Louzada M, LeBlanc R, Sebag M, Song K, Jimenez-Zepeda VH, Kotb R, Kardjadj M, Mian H, White D, Stakiw J, Aslam M, Reiman A, Gul E, Reece D.